RainDance to Co-Develop Next-Gen Sequencing Products for ADME Applications with Ambry and Roche

Under its deal with Ambry, the companies will develop a screening panel to sequence the coding regions of 220 key drug metabolism-linked genes; while in a separate deal Roche has agreed to commercialize an ADME gene screening research panel covering 100 percent of 36 genes that will be available on both the GS FLX and the GS Junior systems.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.